课题基金 / 基金详情

IP PRIMING WITH RIFNG AND RIL 2 IN IP ADOPTIVE IMMUNOTHERAPY OF OVARIAN CANCER

IP PRIMING WITH RIFNG AND RIL 2 IN IP ADOPTIVE IMMUNOTHERAPY OF OVARIAN CANCER
RIFNG 和 RIL 2 在卵巢癌 IP 过继免疫治疗中的 IP 启动
批准号：
5224116
负责人：
RALPH Stuart FREEDMAN
金额：
$0.0万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/5224116
关键词：
clinical research clinical trials drug screening /evaluation female human subject human therapy evaluation interferons interleukin 2 neoplasm /cancer immunotherapy ovary neoplasms tumor infiltrating lymphocyte

项目摘要

项目成果

RALPH Stuart FREEDMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The long-term objectives are to develop new and effective treatment approaches for epithelial ovarian cancer. The hypotheses to be tested are that ovarian tumor infiltrating lymphocyte (TIL)-derived T-cell lines can be developed from peritoneal exudate cells of EOC patients after intraperitoneal priming with interferon-gamma followed by low doses of interleukin-2. The focus is on elucidating the mechanisms of action in vivo of these TILs, and can be addressed only in conjunction with this clinical trial.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Autologous therapeutic tumor vaccine + IFN-gamma
Phase ii intraperitoneal rhIL 12
Phase ii intraperitoneal rhIL 12
B7.1 COSTIMULATION IN OVARIAN CANCER
海外基金